黄素:生物化学,药理学,先进的药物输送系统,以及其在抗癌方面的表观遗传作用
Shukur Wasman Smail1,2, Peter Bergsten3,4,5, Kalthum Othman Taha2
1College of Pharmacy, Cihan University-Erbil, Erbil, Iraq.
Frontiers in pharmacology
|December 1, 2025
概括
黄是一种黄化合物,由于其抗氧化,抗炎和抗癌作用,它对癌症的预防和治疗具有前途. 先进的输送系统提高了其生物可用性,而其表观遗传作用有助于重新激活瘤抑制基因.
科学领域:
- 药理学和表观遗传学
- 癌症生物学 癌症生物学
- 自然产品化学 自然产品化学
背景情况:
- 来自黄的黄素具有与癌症相关的显著药理和表观遗传特性.
- 它的治疗潜力受到溶解性差和生物可用性低的阻碍.
- 纳米技术为提高黄素的输送和有效性提供了解决方案.
研究的目的:
- 审查黄素在癌症中的生化,药理和分子作用.
- 探索黄素对基因表达和癌症的多方面的表观遗传影响.
- 讨论基于纳米技术的策略,以改善黄素的临床应用.
主要方法:
- 关于黄素影响的综合文献综述.
- 分析黄素调节的分子信号通路 (例如NF-κB,PI3K/Akt).
- 检查黄素的表观遗传机制,包括DNA甲基化,基因素修饰和非编码RNA调节.
主要成果:
- 黄素表现出抗氧化,抗炎和抗癌活性.
- 它调节关键的与癌症相关的信号通路.
- 黄素影响DNA甲基化,基因素乙化,非编码RNA和RNA甲基化 (m6A).
结论:
- 黄素的分子和表观遗传效应将其定位为癌症预防和治疗的有前途的多目标药物.
- 基于纳米技术的输送系统对于克服生物可用性限制至关重要.
- 需要进一步的药物遗传学和临床研究来优化黄素配方的治疗用途.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Cancer
53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer Prevention
7.6K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
7.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


